231 related articles for article (PubMed ID: 28342266)
1. Increased number of mast cells in the dermis in actinic keratosis lesions effectively treated with imiquimod.
Oyama S; Funasaka Y; Tsuchiya SI; Kawana S; Saeki H
J Dermatol; 2017 Aug; 44(8):944-949. PubMed ID: 28342266
[TBL] [Abstract][Full Text] [Related]
2. Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.
Torres A; Storey L; Anders M; Miller RL; Bulbulian BJ; Jin J; Raghavan S; Lee J; Slade HB; Birmachu W
J Transl Med; 2007 Jan; 5():7. PubMed ID: 17257431
[TBL] [Abstract][Full Text] [Related]
3. Association between the clinical and histopathological classifications of actinic keratosis and the efficacy of topical imiquimod treatment.
Yu A; Tanizaki H; Kokunai Y; Kaneda K; Sugimoto A; Otsuka T; Kurokawa T; Moriwaki S
J Dermatol; 2018 Apr; 45(4):496-500. PubMed ID: 29265412
[TBL] [Abstract][Full Text] [Related]
4. Comparative study for the effect of photodynamic therapy, imiquimod immunotherapy and combination of both therapies on 40 lesions of actinic keratosis in Japanese patients.
Tanaka N; Ohata C; Ishii N; Imamura K; Ueda A; Furumura M; Yasumoto S; Kawakami T; Tsuruta D; Hashimoto T
J Dermatol; 2013 Dec; 40(12):962-7. PubMed ID: 24147543
[TBL] [Abstract][Full Text] [Related]
5. Microarray analysis of aberrant gene expression in actinic keratosis: effect of the Toll-like receptor-7 agonist imiquimod.
Torres A; Storey L; Anders M; Miller RL; Bulbulian BJ; Jin J; Raghavan S; Lee J; Slade HB; Birmachu W
Br J Dermatol; 2007 Dec; 157(6):1132-47. PubMed ID: 17944981
[TBL] [Abstract][Full Text] [Related]
6. Treatment of actinic keratoses with 5% topical imiquimod: a multicenter prospective observational study from 93 Austrian office-based dermatologists.
Strohal R; Kerl H; Schuster L
J Drugs Dermatol; 2012 May; 11(5):574-8. PubMed ID: 22527424
[TBL] [Abstract][Full Text] [Related]
7. [New perspective in immunotherapy: local imiquimod treatment].
Kemény L; Nagy N
Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
[TBL] [Abstract][Full Text] [Related]
8. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
Swanson N; Smith CC; Kaur M; Goldenberg G
J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type.
Alomar A; Stockfleth E; Dirschka T; Gupta G; Aractingi S; Dakovic R; Peris K
J Drugs Dermatol; 2016 Mar; 15(3):285-9. PubMed ID: 26954313
[TBL] [Abstract][Full Text] [Related]
10. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Swanson N; Smith CC; Kaur M; Goldenberg G
J Drugs Dermatol; 2014 Feb; 13(2):166-9. PubMed ID: 24509967
[TBL] [Abstract][Full Text] [Related]
11. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis.
Persaud AN; Shamuelova E; Sherer D; Lou W; Singer G; Cervera C; Lamba S; Lebwohl MG
J Am Acad Dermatol; 2002 Oct; 47(4):553-6. PubMed ID: 12271300
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment.
Ortonne JP; Gupta G; Ortonne N; Duteil L; Queille C; Mallefet P
Exp Dermatol; 2010 Jul; 19(7):641-7. PubMed ID: 20201959
[TBL] [Abstract][Full Text] [Related]
13. Imiquimod and lymphatic field clearance: a new hypothesis based on a remote immune action on skin cancer.
Akkilic-Materna M; Massone C; Komericki P
Acta Derm Venereol; 2011 Jun; 91(4):432-5. PubMed ID: 21547348
[TBL] [Abstract][Full Text] [Related]
14. Topical Imiquimod in the Treatment of Conjunctival Actinic Keratosis.
Rowlands MA; Giacometti JN; Servat J; Materin MA; Levin F
Ophthalmic Plast Reconstr Surg; 2017; 33(1):e21-e23. PubMed ID: 25853505
[TBL] [Abstract][Full Text] [Related]
15. Imiquimod in dermatology: an overview.
Hanna E; Abadi R; Abbas O
Int J Dermatol; 2016 Aug; 55(8):831-44. PubMed ID: 27387373
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of imiquimod 3.75% from Lmax according to the number of actinic keratosis lesions.
Peris K; Stockfleth E; Gupta G; Aractingi S; Dakovic R; Dirschka T; Alomar A
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2470-3. PubMed ID: 25351284
[TBL] [Abstract][Full Text] [Related]
17. Effects of topical piroxicam and sun filters in actinic keratosis evolution and field cancerization: a two-center, assessor-blinded, clinical, confocal microscopy and dermoscopy evaluation trial.
Agozzino M; Russo T; Franceschini C; Mazzilli S; Garofalo V; Campione E; Bianchi L; Milani M; Argenziano G
Curr Med Res Opin; 2019 Oct; 35(10):1785-1792. PubMed ID: 31148490
[No Abstract] [Full Text] [Related]
18. Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis.
Gupta G; Stockfleth E; Peris K; Aractingi S; Alomar A; Dakovic R; Dirschka T
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1840-2. PubMed ID: 25174261
[TBL] [Abstract][Full Text] [Related]
19. Clinical, dermoscopic and immunohistochemical assessment of actinic keratoses and evaluation of the effectiveness of diclofenac therapy with immunohistochemical analysis.
Çayirli M; Köse O; Demiriz M
Arch Dermatol Res; 2013 Jul; 305(5):389-95. PubMed ID: 23397597
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series.
Tambone S; Fargnoli MC; Capizzi R; Peris K
G Ital Dermatol Venereol; 2018 Jun; 153(3):333-337. PubMed ID: 26439591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
